If a drug is considered as an appropriate comparator, the drug must have an approval for the area of application.
2
If a non-drug treatment is considered as an appropriate comparator, it must be performable within the framework of the statutory health insurance (Gesetzliche Krankenversicherung).
3
Preferably, drugs or non-drug treatments whose patient-relevant benefit has already been determined by G-BA, must be taken into consideration as an appropriate comparator.
4
The appropriate comparator must belong to the appropriate therapy in the area of application, according to the general recognized state of the art of medical knowledge.
 Melanoma in adults is a highly dynamic therapeutic space. Melanoma was, therefore, chosen to exemplify G-BA's approach of how to account advances in medical treatment when defining the appropriate comparator.
 A database containing all assessed AMNOG dossiers published on the G-BA website (https://www.g-ba.de) from January 2011 until the end of August 2018 was screened for dossiers in melanoma.  For all relevant dossiers the official documentation of G-BA's decision-making (Tragende Gründe) was screened for further information on the appropriate comparator and granted added medical benefit.  Information concerning the defined appropriate comparator by G-BA and the decision on added benefits were extracted for relevant dossiers. Table 2 ).  In the relevant dossiers in melanoma appropriate comparators were defined as one specific drug, a list of equivalent drugs (out of which the manufacturer can choose freely), patient individual therapy, and best supportive care (Tables 3-5 ).  Although the product labels of ipilimumab, nivolumab, pembrolizumab and talimogen laherparepvec do not take BRAF mutation status into account, G-BA considered two subpopulations (BRAF+/BRAF-). As those subpopulations are considered to be different entities in clinical guidelines and are managed differently in clinical practice, specific appropriate comparators therapies were defined by G-BA based on subpopulations (BRAF+/BRAF-) ( Tables 3 and 4 ) and treatment line regardless of BRAF mutation status ( Table 3) .  Then in 2013, taking the degree of the added medical benefit into account, vemurafenib was defined as appropriate comparator for the dossier of dabrafenib.  Until 2016 vemurafenib remained the appropriate comparator for the nine following melanoma dossiers. This static constellation might be attributable to the fact that for five dossiers (dabrafenib, 2013; ipilimumab (firstline), 2013; nivolumab, 2015; pembrolizumab, 2015; trametinib, 2015) no added medical benefit had been attested.  In 2015, both for dabrafenib+trametinib and cobimetinib+vemurafenib a considerable added medical benefit was assigned by G-BA.  Again, and similar to the assessment of vemurafenib in 2012, G-BA took the added medical benefit of dabrafenib+trametinib and cobimetinib+vemurafenib into account and included these regimens in the list of appropriate comparators for talimogen laherparepvec and nivolumab+ipilimumab.
 Labels nonspecific to BRAF mutation status were segmented by G-BA in subpopulations by BRAF mutation status and therapy lines (if in line with the label). Thus, individual appropriate comparator therapies were defined for those subpopulations for the assessments of ipilimumab, nivolumab, pembrolizumab, talimogen laherparepvec and nivolumab+ipilimumab ( Table 2) .  G-BA does take the dynamic nature of treatment of an indication into account. For melanoma, the observed time span for updating the appropriate comparator is between one and two years. This could be attributable to the fact that a considerable added medical benefit in overall survival was attested and, in parallel, a fast uptake in medical practice occurred. Whether these findings can be transferred to other indications is out of the scope of this analysis.  Even compounds with no added benefit (ipilimumab first-line, 2013; Table 1 , Criterion 3) were chosen as appropriate comparators. It can be assumed that other reasons are being factored in the decision defining the appropriate comparator (e.g., clinical practice).  The uncertainty in the treatment guidelines and medical practice (Table 1, Criterion 4) translates into the setting of patient-individual care as appropriate comparator for pretreated patients. (Table 3) and BRAF-( Table 4) . For the BRAF-population dacarbazine was defined as the appropriate comparator.  Despite the fact that for ipilimumab, both in BRAF+ and in BRAF-patients, no added medical benefit was attested by G-BA, ipilimumab was added to the list of appropriate comparators for nivolumab (2015) and was the sole appropriate comparator for pembrolizumab (2015) . For talimogen laherparepvec (2016), nivolumab+ipilimumab (2016), and nivolumab+ipilimumab (2017), ipilimumab was initially chosen as the appropriate comparator.  The considerable added medical benefit for nivolumab (2015) and pembrolizumab (2015) in overall survival triggered the G-BA to update the initial choice of the appropriate comparator (ipilimumab  nivolumab or pembrolizumab). 
